Markets Nosedive

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

New Chief

New Chief

P&G brings back A.G. Lafley as CEO, McDonald out.  Full Article 

Bernanke Impact

Bernanke Impact

U.S. Fed enters delicate new phase of communication  Full Article | Column 

Ranbaxy Fine

Ranbaxy Fine

Daiichi Sankyo accusation "false and baseless": Singhs  Full Article 

Ad Sales' Scrutiny

Ad Sales' Scrutiny

Google faces new federal antitrust probe - source.  Full Article 

Tax Holiday

Tax Holiday

Apple enjoyed Irish tax holiday from the start.  Full Article 

FDA Woes

FDA Woes

Wockhardt says FDA alert affects potential sales of $100 million.  Full Article 

Goldman Safeguards

Goldman Safeguards

Goldman unveils checks on conflicts in bid to fix image.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-Indian shares gain; SBI, Sun Pharma up

Related Topics

Stocks

   

Wed Feb 6, 2013 10:06am IST

* The BSE index gains 0.21 percent, and the 50-share
NSE index also rises 0.2 percent, after dropping to more
than a four-week low on Tuesday and falling for five sessions
out of six.
* Investors are cautious ahead of the 2013/14 federal budget to
be unveiled later this month, which is seen as a key test of
commitments to shore up finance.
* Foreign institutional investors can buy up to 49 percent
shares in Infrastructure Developers Ltd and up to 30
percent in Radico Khaitan Ltd, the Reserve Bank of
India said, raising the limits under portfolio investment
scheme. 
* IRB Infra share gain 2.5 percent, Radico shares rise 3
percent.
* Leading the rise: State Bank of India rises 0.7
percent on value buying, while Sun Pharmaceuticals up
0.9 percent on U.S. nod for cancer drug.

 (manoj.dharra@thomsonreuters.com;
manoj.dharra.thomsonreuters.com@reuters.net)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.